-
Understanding the Needs and Aspirations of Emerging HEOR Talent: Results From the ISPOR New Professional and Student Survey
Sep 9, 2025, 16:22 PM -
The Economic Case for Gender Equity: How Closing the Women’s Health Gap Benefits Healthcare Systems and Economies
Sep 9, 2025, 16:22 PM -
From Evidence to Enforcement? Implications of the 2025 SVR Report for Pharmaceutical Pricing and Orphan Drug Policy in Germany
Sep 9, 2025, 16:22 PM -
Assessment of Health State Utilities Associated With Treatment for Chronic Hepatitis B Virus (HBV) Infection
Sep 9, 2025, 16:22 PM -
HTA Readiness for Tumor-Agnostic Therapies: Lessons From Analogues Across Major Markets
Sep 9, 2025, 16:22 PM -
Clinical Benefit vs. Reimbursement Decisions: Examining Misalignments Between ESMO-MCBS and HTA Outcomes in Oncology
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Ocrelizumab for Treating Relapsing Multiple Sclerosis in Austria
Sep 9, 2025, 16:22 PM -
Balancing Fit and Accuracy: Evaluating Survival Model Projections With Immature Data in Health Technology Assessments
Sep 9, 2025, 16:22 PM -
Building Trust in Living Evidence Synthesis: A Delphi Process for Best Practices
Sep 9, 2025, 16:22 PM -
Intrauterine Tamponade Balloon Complications in MAUDE Database a Critical Analysis
Sep 9, 2025, 16:22 PM -
Comparative Clinical Effectiveness in Skin Cancer: Lessons From HTA Decision Making in EU4, UK, and Australia
Sep 9, 2025, 16:22 PM -
Hospitalizations for Myasthenia Gravis: Pre- and Post-COVID Trends
Sep 9, 2025, 16:22 PM -
The Real-World Impact of Step Therapy and Prior Authorization on Patients, Clinicians, and US Health Plans: Lessons to Be Learned in Europe
Sep 9, 2025, 16:22 PM -
NICE Decisions in the Southwest Quadrant
Sep 9, 2025, 16:22 PM -
The Effects of Pooling Treatment Effects Targeting Treatment Policy and Hypothetical Estimands With Rank-Preserving Structural Failure Time Model in Oncology Aggregate-Level Meta-Analyses
Sep 9, 2025, 16:22 PM -
Quantifying the Economic Burden of Osteoarthritis in Portugal: Insights From a Patient Journey Model
Sep 9, 2025, 16:22 PM -
Definitive Staging and Perioperative Treatment for Resectable Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC): A UK Perspective
Sep 9, 2025, 16:22 PM -
Effect of the Inflation Reduction Act on Drug Innovation
Sep 9, 2025, 16:22 PM -
Integrating Environmental Sustainability Into Cost-Effectiveness Analysis and Value Demonstration: A Multidimensional Framework
Sep 9, 2025, 16:22 PM -
Expert Consensus on the Clinical and Economic Value of Advanced Wound-Care Products in Mexico: Results From a Delphi Panel
Sep 9, 2025, 16:22 PM